Opinion
Video
Navigating Cost Considerations in Treatment Selection of mCRC Agents
Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC). They also discuss how payer requirements influence treatment sequencing and decision-making in the third-line setting and how the costs associated with adverse events across different third-line treatments affect treatment selection.
Video content above is prompted by the following:
- What are the key payer-related challenges (eg, step edits, prior authorizations) that impact access to third-line therapies for patients with mCRC?
- How do payer requirements influence treatment sequencing and decision-making in the third-line setting?
- How do the costs associated with adverse events across the different third-line treatments (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab) influence treatment selection?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
